Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | THRB | P10828 | 4/20 | 0.45 |
| ▸ | TP53 | P04637 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | BACE1 | P56817 | 5/20 | 0.43 |
| ▸ | DTYMK | P23919 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.39 |
| ▸ | KRAS | P01116 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3527243 | 0.82 | NPC1 (0.51) | LMNATHRBTP53MAPTACHE | |
| SCHEMBL3523914 | 0.82 | BACE1 (0.49) | LMNAMAPTBACE1SCD5 | |
| SCHEMBL6171513 | 0.81 | BACE1 (0.41) | BACE1DTYMKCHRM2CHRM4CHRM1 | |
| SCHEMBL3522533 | 0.81 | KMT2A (0.48) | LMNATHRBTP53MAPTACHE | |
| SCHEMBL30476287 | 0.79 | CHRM2 (0.42) | TP53MAPTBACE1ACHECHRM2 | |
| SCHEMBL31588744 | 0.77 | ACHE (0.41) | ACHESCD5 | |
| SCHEMBL31588628 | 0.76 | DPP4 (0.40) | ACHESCD5 | |
| SCHEMBL31588630 | 0.76 | DPP4 (0.40) | ACHESCD5 | |
| SCHEMBL21274172 | 0.75 | BACE1 (0.49) | LMNAMAPTBACE1SCD5 | |
| SCHEMBL30546116 | 0.75 | BACE1 (0.49) | LMNAMAPTBACE1SCD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642276-B2 | Fused heteroaryl derivatives for use as P38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642276-B2 | Fused heteroaryl derivatives for use as P38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642276-B2 | Fused heteroaryl derivatives for use as P38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-05 | — | — | US | disclosed |
| EP-1531812-B1 | FUSED HETEROARYL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS IN THE TREATMENT OF I.A. RHEUMATOID ARTHRITIS | SMITHKLINE BEECHAM CORP (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20060122221-A1 | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis | SMITHKLINE BEECHAM CORPORATION | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122221-A1 | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis | MAPK7, CNKSR1, MAPK1 | LMNA 3838/4885THRB 1832/4885TP53 2766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.